ライフサイエンスコーパス: we enrolled patients

1 We enrolled patients 6 months of age or older who presented w

2 In this phase 1/2, multicentre, open-label study, we enrolled patients (age >/=18 years) with urothelial carcin

3 e 3 study (CALIMA) undertaken at 303 sites in 11 countries, we enrolled patients aged 12-75 years with severe asthma unco

4 We enrolled patients aged 13 years or older with functional C

5 We enrolled patients aged 18 years and older with a histologi

6 In this multicentre, phase 3, randomised, controlled trial, we enrolled patients aged 18 years or older from 129 UK centr

7 In this randomised, placebo-controlled, double-blind study, we enrolled patients aged 18 years or older who had an Eczema

8 We enrolled patients aged 18 years or older who were identifi

9 f a multicentre, open-label, non-randomised, phase 2 trial, we enrolled patients aged 18 years or older with a documented

10 In this phase 1-2 trial, we enrolled patients aged 18 years or older with acute myeloi

11 We enrolled patients aged 18 years or older with HCV genotype

12 We enrolled patients aged 18 years or older with intermediate

13 In this non-randomised, open-label, phase 2 trial, we enrolled patients aged 18 years or older with melanoma or

14 e, open-label, parallel-group, randomised controlled trial, we enrolled patients aged 18 years or older with type 2 diabe

15 We enrolled patients aged 18 years or younger with new-onset

16 In this prospective cohort study, we enrolled patients aged 2-65 years with uncomplicated P fal

17 In this phase 1 study, we enrolled patients aged 20 years or older with Eastern Coop

18 s non-randomised, open-label, single-centre, phase 2 trial, we enrolled patients aged 3-21 years who had medulloblastoma.

19 randomised, double-blind, placebo-controlled, phase 2 trial we enrolled patients aged 35-75 years with basal-cell nevus s

20 We enrolled patients aged 65 years or older, who were admitte

21 double-blind, randomised, placebo-controlled phase 2 trial, we enrolled patients (aged 18-80 years) with a clinical diagn

22 ouble-blind, placebo-controlled, randomised, phase 3 trial, we enrolled patients at 226 study centres in the USA and Cana

23 randomised, double-blind, placebo-controlled phase 2 study, we enrolled patients at 36 referral sites in North America, E

24 In this double-blind, placebo-controlled, phase 3 study we enrolled patients from 311 centres in 16 countries across

25 We enrolled patients from across the US National Clinical Tri

26 We enrolled patients from five academic PICUs between 2008 an

27 We enrolled patients from primary or specialty care clinics i

28 We enrolled patients (>/=18 years) with Wilson's disease who

29 We enrolled patients in this open-label, Simon two-stage, sin

30 n a prospective, open-label, multicenter, randomized trial, we enrolled patients presenting with symptoms suggestive of a

31 We enrolled patients who had squamous or non-squamous non-sma

32 We enrolled patients with a diagnosis of acute myeloid leukae

33 ective, randomized, double-blind, placebo-controlled trial, we enrolled patients with atrial fibrillation who were schedu

34 We enrolled patients with diagnosis of refractory anaemia wit

35 ter, randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocard

36 We enrolled patients with genetically confirmed Friedreich's

37 We enrolled patients with histologically proven OSSN aged at

38 In this observational cohort study, we enrolled patients with idiopathic or heritable pulmonary a

39 We enrolled patients with IPF diagnosis in a six-cohort study

40 We enrolled patients with metastatic papillary, chromophobe,

41 We enrolled patients with multiple sclerosis, aged 18-50 year

42 We enrolled patients with occlusion of the intracranial inter

43 We enrolled patients with PD-L1-positive recurrent or metasta

44 We enrolled patients with primary refractory or relapsed myel

45 s global, open-label, randomised, controlled phase 3 trial, we enrolled patients with relapsed CLL progressing less than

46 Methods We enrolled patients with relapsed or refractory HL whose dis

47 We enrolled patients with severe (>/=70%) single-vessel steno

48 In this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma

49 In this prospective phase 2 trial, we enrolled patients with treatment-naive, asymptomatic, meta

50 We enrolled patients with treatment-refractory metastatic SCC